Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
The article tells about the role of angiotensin II receptor blockers in risk management of cardiovascular and renal complications in diabetes mellitus. The results of clinical trials of Irbesartan (Aprovel®) are demonstrated.
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
Remedium Group LLC
2013-12-01
|
| Seri Bilgileri: | Медицинский совет |
| Konular: | |
| Online Erişim: | https://www.med-sovet.pro/jour/article/view/1100 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|